Immunome, Inc. (IMNM)
NASDAQ: IMNM · IEX Real-Time Price · USD
13.83
-0.57 (-3.96%)
At close: May 17, 2024, 4:00 PM
13.84
+0.01 (0.07%)
After-hours: May 17, 2024, 7:48 PM EDT
Company Description
Immunome, Inc., a biotechnology company, develops targeted cancer therapies.
The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Immunome, Inc.
| Country | United States |
| Founded | 2006 |
| IPO Date | Oct 2, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Dr. Clay B. Siegall Ph.D. |
Contact Details
Address: 18702 N. Creek Parkway, Suite 100 Bothell, Washington 98011 United States | |
| Phone | 610-321-3700 |
| Website | immunome.com |
Stock Details
| Ticker Symbol | IMNM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001472012 |
| CUSIP Number | 45257U108 |
| ISIN Number | US45257U1088 |
| Employer ID | 77-0694340 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Clay B. Siegall Ph.D. | President, Chief Executive Officer and Chairman |
| Max Rosett | Interim Chief Financial Officer and Executive Vice President of Operations |
| Robert Lapetina | Principal Accounting Officer |
| Philip Roberts | Chief Technical Officer |
| Dr. Jack Higgins Ph.D. | Chief Scientific Officer |
| Sandra G. Stoneman Esq., J.D. | Chief Legal Officer, General Counsel and Corporate Secretary |
| Bruce Turner M.D., Ph.D. | Chief Strategy Officer |
| Dr. Robert J. Lechleider M.D. | Chief Medical Officer |
| Kinney Horn | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2024 | 424B5 | Filing |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| Apr 30, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2024 | 8-K | Current Report |
| Apr 3, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Apr 3, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |